USFDAMay 29, 2026, 02:02 PM
MannKind Afrezza® FDA Approved for Children with Diabetes
AI Summary
MannKind Corporation announced that the FDA has approved Afrezza® for use in children and adolescents aged 6 and older living with diabetes. To discuss this significant regulatory milestone, the company's management will host a conference call on Friday, May 29, 2026, at 4:30 p.m. Eastern. The call will feature presentations from CEO Michael Castagna and Senior Vice President Kevin Kaiserman, with webcast details available on the company's investor relations website.
Key Highlights
- FDA approved Afrezza® for children and adolescents aged 6 and older with diabetes.
- Management will host a conference call on May 29, 2026, at 4:30 p.m. Eastern.
- CEO Michael Castagna and SVP Kevin Kaiserman will present on the call.
- Live audio webcast and recorded versions will be available on MannKind's investor website.
Price Impact
More from MNKD